VentriPoint Diagnostics Ltd Market Cap ($11.16 Million)
Market Cap & Net Worth: VentriPoint Diagnostics Ltd (VPT)
VentriPoint Diagnostics Ltd market cap. VentriPoint Diagnostics Ltd (V:VPT) has a market capitalization of $11.16 Million (CA$15.43 Million) as of November 1, 2026. Listed on the V stock exchange, this Canada-based company holds position #26665 globally and #1078 in its home market, demonstrating a -11.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VentriPoint Diagnostics Ltd's stock price CA$0.08 by its total outstanding shares 192877941 (192.88 Million). Also see VPT cash flow metrics for how efficiently the company converts equity into cash flow.
VentriPoint Diagnostics Ltd Market Cap History (2015–2026)
VentriPoint Diagnostics Ltd market cap history from 2015 to 2026. Data shows change from $39.07 Million to $11.16 Million (-13.57% CAGR). Check current stock price of VentriPoint Diagnostics Ltd for real-time trading data and today's change.
VentriPoint Diagnostics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VentriPoint Diagnostics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is VentriPoint Diagnostics Ltd growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
108.56x
VentriPoint Diagnostics Ltd's market cap is 108.56 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $16.74 Million | $209.48K | -$2.62 Million | 79.93x | N/A |
| 2017 | $43.25 Million | $38.91K | -$3.70 Million | 1111.75x | N/A |
| 2018 | $21.63 Million | $60.18K | -$2.08 Million | 359.38x | N/A |
| 2019 | $11.16 Million | $81.02K | -$3.32 Million | 137.76x | N/A |
| 2020 | $12.56 Million | $36.02K | -$1.85 Million | 348.65x | N/A |
| 2022 | $37.67 Million | $68.17K | -$4.87 Million | 552.64x | N/A |
| 2023 | $41.86 Million | $49.18K | -$4.87 Million | 851.06x | N/A |
| 2024 | $13.95 Million | $95.17K | -$4.92 Million | 146.60x | N/A |
| 2025 | $19.53 Million | $179.93K | -$3.20 Million | 108.56x | N/A |
Competitor Companies of VPT by Market Capitalization
Companies near VentriPoint Diagnostics Ltd in the global market cap rankings as of November 1, 2026. Also see VPT current and non-current assets for a full breakdown of the balance sheet.
Key companies related to VentriPoint Diagnostics Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #114 globally with a market cap of $184.67 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #215 globally with a market cap of $111.95 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #225 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #241 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #114 | Abbott Laboratories | NYSE:ABT | $184.67 Billion | $106.20 |
| #215 | Stryker Corporation | NYSE:SYK | $111.95 Billion | $291.86 |
| #225 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $96.54 |
| #241 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of VentriPoint Diagnostics Ltd (2015–2026)
Market capitalization of VentriPoint Diagnostics Ltd from 2015 to today. Between 2015 and today, VentriPoint Diagnostics Ltd's market cap moved from $39.07 Million to $ 11.16 Million, with a yearly change of -13.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$11.16 Million | -42.86% |
| 2025 | CA$19.53 Million | +40.00% |
| 2024 | CA$13.95 Million | -66.67% |
| 2023 | CA$41.86 Million | +11.11% |
| 2022 | CA$37.67 Million | -21.74% |
| 2021 | CA$48.14 Million | +283.33% |
| 2020 | CA$12.56 Million | +12.50% |
| 2019 | CA$11.16 Million | -48.39% |
| 2018 | CA$21.63 Million | -50.00% |
| 2017 | CA$43.25 Million | +158.33% |
| 2016 | CA$16.74 Million | -57.14% |
| 2015 | CA$39.07 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of VentriPoint Diagnostics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.16 Million USD |
| MoneyControl | $11.16 Million USD |
| MarketWatch | $11.16 Million USD |
| marketcap.company | $11.16 Million USD |
| Reuters | $11.16 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About VentriPoint Diagnostics Ltd
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), which transforms standard 2D and 3D echocardiography and a medical imaging system that is used to generate three-dimensional models with critical volume and functional m… Read more